Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging

Ihab R Kamel, Eleni A Liapi, Diane K. Reyes, Marianna Zahurak, David A. Bluemke, Jean François H Geschwind

Research output: Contribution to journalArticle

Abstract

Purpose: To prospectively assess serial changes in contrast material- enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging values within 1 month after transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Materials and Methods:Institutional review board approval was obtained for this prospective HIPAA-compliant study. MR imaging was performed before and within 24 hours after TACE in 24 patients with HCC (21 male, three female; mean age, 59 years and 62 years, respectively). Serial MR imaging was subsequently performed 1, 2, 3, and 4 weeks after therapy. The imaging protocol included fast spin-echo T2- weighted MR imaging, breath-hold DW echo-planar MR imaging, and breath-hold unenhanced and contrast-enhanced T1-weighted three-dimensional fat-suppressed gradient-recalled-echo MR imaging in the arterial and portal venous phases. Tumor size, enhancement, and apparent diffusion coefficient (ADC) values were recorded before and sequentially after treatment. Regression models for the correlated data were used to assess changes in these parameters over time after TACE. Results: Mean tumor size was 7.5 cm and was unchanged up to 4 weeks after therapy. Reduction in tumor enhancement in the arterial phase occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.001). Reduction in tumor enhancement in the portal venous phase also occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.0003). The increase in tumor ADC value was significant 1-2 weeks after therapy (P =.004), borderline significant 3 weeks after therapy, and insignificant 24 hours and 4 weeks after therapy. Conclusion: Significant reduction in tumor enhancement occurred within 24 hours after TACE and persisted up to 4 weeks after TACE. Lesser changes in the ADC value appeared 1 week after TACE, persisted through 2 weeks after TACE, and became less apparent 3 and 4 weeks after TACE. No change in tumor size was recorded during the follow-up period.

Original languageEnglish (US)
Pages (from-to)466-473
Number of pages8
JournalRadiology
Volume250
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Blood Vessels
Hepatocellular Carcinoma
Magnetic Resonance Imaging
Neoplasms
Therapeutics
Echo-Planar Imaging
Health Insurance Portability and Accountability Act
Diffusion Magnetic Resonance Imaging
Research Ethics Committees
Contrast Media
Fats

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Unresectable hepatocellular carcinoma : Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. / Kamel, Ihab R; Liapi, Eleni A; Reyes, Diane K.; Zahurak, Marianna; Bluemke, David A.; Geschwind, Jean François H.

In: Radiology, Vol. 250, No. 2, 02.2009, p. 466-473.

Research output: Contribution to journalArticle

Kamel, Ihab R ; Liapi, Eleni A ; Reyes, Diane K. ; Zahurak, Marianna ; Bluemke, David A. ; Geschwind, Jean François H. / Unresectable hepatocellular carcinoma : Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. In: Radiology. 2009 ; Vol. 250, No. 2. pp. 466-473.
@article{bdda556e444b4825a4f1c728843d326a,
title = "Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging",
abstract = "Purpose: To prospectively assess serial changes in contrast material- enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging values within 1 month after transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Materials and Methods:Institutional review board approval was obtained for this prospective HIPAA-compliant study. MR imaging was performed before and within 24 hours after TACE in 24 patients with HCC (21 male, three female; mean age, 59 years and 62 years, respectively). Serial MR imaging was subsequently performed 1, 2, 3, and 4 weeks after therapy. The imaging protocol included fast spin-echo T2- weighted MR imaging, breath-hold DW echo-planar MR imaging, and breath-hold unenhanced and contrast-enhanced T1-weighted three-dimensional fat-suppressed gradient-recalled-echo MR imaging in the arterial and portal venous phases. Tumor size, enhancement, and apparent diffusion coefficient (ADC) values were recorded before and sequentially after treatment. Regression models for the correlated data were used to assess changes in these parameters over time after TACE. Results: Mean tumor size was 7.5 cm and was unchanged up to 4 weeks after therapy. Reduction in tumor enhancement in the arterial phase occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.001). Reduction in tumor enhancement in the portal venous phase also occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.0003). The increase in tumor ADC value was significant 1-2 weeks after therapy (P =.004), borderline significant 3 weeks after therapy, and insignificant 24 hours and 4 weeks after therapy. Conclusion: Significant reduction in tumor enhancement occurred within 24 hours after TACE and persisted up to 4 weeks after TACE. Lesser changes in the ADC value appeared 1 week after TACE, persisted through 2 weeks after TACE, and became less apparent 3 and 4 weeks after TACE. No change in tumor size was recorded during the follow-up period.",
author = "Kamel, {Ihab R} and Liapi, {Eleni A} and Reyes, {Diane K.} and Marianna Zahurak and Bluemke, {David A.} and Geschwind, {Jean Fran{\cc}ois H}",
year = "2009",
month = "2",
doi = "10.1148/radiol.2502072222",
language = "English (US)",
volume = "250",
pages = "466--473",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Unresectable hepatocellular carcinoma

T2 - Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging

AU - Kamel, Ihab R

AU - Liapi, Eleni A

AU - Reyes, Diane K.

AU - Zahurak, Marianna

AU - Bluemke, David A.

AU - Geschwind, Jean François H

PY - 2009/2

Y1 - 2009/2

N2 - Purpose: To prospectively assess serial changes in contrast material- enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging values within 1 month after transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Materials and Methods:Institutional review board approval was obtained for this prospective HIPAA-compliant study. MR imaging was performed before and within 24 hours after TACE in 24 patients with HCC (21 male, three female; mean age, 59 years and 62 years, respectively). Serial MR imaging was subsequently performed 1, 2, 3, and 4 weeks after therapy. The imaging protocol included fast spin-echo T2- weighted MR imaging, breath-hold DW echo-planar MR imaging, and breath-hold unenhanced and contrast-enhanced T1-weighted three-dimensional fat-suppressed gradient-recalled-echo MR imaging in the arterial and portal venous phases. Tumor size, enhancement, and apparent diffusion coefficient (ADC) values were recorded before and sequentially after treatment. Regression models for the correlated data were used to assess changes in these parameters over time after TACE. Results: Mean tumor size was 7.5 cm and was unchanged up to 4 weeks after therapy. Reduction in tumor enhancement in the arterial phase occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.001). Reduction in tumor enhancement in the portal venous phase also occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.0003). The increase in tumor ADC value was significant 1-2 weeks after therapy (P =.004), borderline significant 3 weeks after therapy, and insignificant 24 hours and 4 weeks after therapy. Conclusion: Significant reduction in tumor enhancement occurred within 24 hours after TACE and persisted up to 4 weeks after TACE. Lesser changes in the ADC value appeared 1 week after TACE, persisted through 2 weeks after TACE, and became less apparent 3 and 4 weeks after TACE. No change in tumor size was recorded during the follow-up period.

AB - Purpose: To prospectively assess serial changes in contrast material- enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging values within 1 month after transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Materials and Methods:Institutional review board approval was obtained for this prospective HIPAA-compliant study. MR imaging was performed before and within 24 hours after TACE in 24 patients with HCC (21 male, three female; mean age, 59 years and 62 years, respectively). Serial MR imaging was subsequently performed 1, 2, 3, and 4 weeks after therapy. The imaging protocol included fast spin-echo T2- weighted MR imaging, breath-hold DW echo-planar MR imaging, and breath-hold unenhanced and contrast-enhanced T1-weighted three-dimensional fat-suppressed gradient-recalled-echo MR imaging in the arterial and portal venous phases. Tumor size, enhancement, and apparent diffusion coefficient (ADC) values were recorded before and sequentially after treatment. Regression models for the correlated data were used to assess changes in these parameters over time after TACE. Results: Mean tumor size was 7.5 cm and was unchanged up to 4 weeks after therapy. Reduction in tumor enhancement in the arterial phase occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.001). Reduction in tumor enhancement in the portal venous phase also occurred immediately after TACE, with a consistent reduction occurring 1-3 weeks after therapy (P =.0003). The increase in tumor ADC value was significant 1-2 weeks after therapy (P =.004), borderline significant 3 weeks after therapy, and insignificant 24 hours and 4 weeks after therapy. Conclusion: Significant reduction in tumor enhancement occurred within 24 hours after TACE and persisted up to 4 weeks after TACE. Lesser changes in the ADC value appeared 1 week after TACE, persisted through 2 weeks after TACE, and became less apparent 3 and 4 weeks after TACE. No change in tumor size was recorded during the follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=61749090699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749090699&partnerID=8YFLogxK

U2 - 10.1148/radiol.2502072222

DO - 10.1148/radiol.2502072222

M3 - Article

C2 - 19188315

AN - SCOPUS:61749090699

VL - 250

SP - 466

EP - 473

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -